12/30/2018: New potential drugs reverse drug resistance in multiple myeloma model (Reeder M et al. leukemia 2018; DOI: 10.1038/s41375-018-0263-1)
12/29/2018: Efficacy of combination of panitumumab and neoadjuvant chemotherapy in HER-2 negative inflammatory breast cancer (Matsuda N et al. JAMA Onc 2018; 4: 1207-13)
12/23/2018: Adjuvant Trastuzumab Emtansine benefits women with residual HER-2 positive breast cancer (von Minckwitz G et al. N Eng J Med 2018; DOI: 10.1056/NEJMoa1814017)
12/22/2018: Rivaroxaban for deep vein thrombosis prevention in patients with cancer(Khorana A el. ASH 2018, abstr LBA1)
12/16/2018: Extending adjuvant aromatase inhibitor to 10 years prolonged disease-free survival in breast cancer patients (Ohtani S et al. SABCS 2018; abstr GS3-04)
12/15/2018: Combination of CDK4/6 inhibitor palbociclib and letrozole did not offer clinical benefit (Johnson S. JCO 2018; Dec. 6th, doi: 10.1200/JCO.18.01624)
12/9/2018: First-line atezolizumab plus chemotherapy in extensive stage small-cell lung cancer (Leora H et al. New Engl J Med 2018; DOI: 10.1056/NEJMoa1809064)
12/8/2018: A new test can diagnose cancer in 10 minutes? (Sina ABI et al. Nature Communication 2018; 9, Article number: 4915)
12/2/2018: New combination of immunotherapy produced response in difficult-to-treat colorectal cancer (Kuo J et al. 30th EORTC-NCI-AACR Sympo on Mol Targets Cancer Therapeutics 2018; Nov 15 abstr 9)
12/1/2018: Drug combination cleared neuroblastoma in mice (Norris M et al. 30 th EORTC-NCI-AACR Symposium 2018; abstr 24)
11/25/2018: A more effective way to deliver drugs into the brain (Plog BA et al. JCI Insight 2018; 3: e120922)
11/24/2018: Identifying targets of anti-malaria drugs in treating cancer (Rebecca VW et al. Cancer Discov 2018; November 15; DOI: 10.1158/2159-8290.CD-18-07)
11/18/2018: A new strategy to reduce bone metastases in breast cancer (Wang H et al. Cancer cell 2018； 34: 823-39)
11/17/2018: Intravesicular installation of gemcitabine for low grade bladder cancer (Messing EM et al. JAMA 2018: 319: 1880-8)
11/11/2018: FDA approved Nivolumab in small cell lung cancer (https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617370.htm; Antonia SJ et al. J Clin Oncol 2016; 34: suppl; abstr 100)
11/10/2018: Mesothelin CAR T cell therapy in malignant pleural disease is promising (Adusumilli PS et al. Am Soc Gene and Cell therapy Meeting 2018; Abstr 342)
11/4/2018: Comparison of complication rates among different techniques for breast reconstruction following mastectomy (Bennett KG et al. JAMA Surg 2018; 153：901-8)
11/3/2018: ACE inhibitors and risk of lung cancer (Hicks BM et al. Br Med J 2018; 363: k4209)
10/28/2018: Dual stain test may guide HPV-positive women for future screening follow-ups (https://www.cancer.gov/news-events/cancer-currents-blog/2018/dual-stain-test-cervical-hpv-positive)
10/27/2018: Results of the Impassion130 trial: Atezolizumab and nab-paclitaxel combination has PFS benefit in first line treatment for advanced triple-negative breast cancer (Schmid P e tal. ESMO, 2018; Abstr LBA1-PR)
10/21/2018: FDA banned 7 ingredients found in candy, baked food, gum and beverages due to their links to cancer (https://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm622475.htm)
10/20/2018: Potential benefit of anti-inflammatory therapy for lymphedema (Rockson SG et al. JCI Insight. 2018; 3(20): e123775 10.1172/jci.insight.123775)
10/14/2018: Adding HPV vaccine to immune checkpoint inhibitor in incurable HPV19-related cancer (Massarelli E et al. JAMA Onc 2018; DOI:10.1001/jamaoncol.2018.4051)
10/13/2018: FDA expands HPV vaccine to cover adults 27-45 years of age (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm)
10/7/2018: Uncommon lethal complications of immune checkpoint inhibitors (Wang DY et al. JAMA ONc 2018; doi:10.1001/jamaoncol.2018.3923)
10/6/2018: Combination of anti-PD-1 and anti CTL-4 target therapy benefited more recurrent ovarian cancer patients (Burger R et al. Biennial Meeting of the Int Gyneoncolog Cancer Soc 2018; Kyoto, Japan. Abstract presentation)
9/30/2018: Mutation identified in appendiceal cancer (Celina S.P.A，J Clin Onc Precision Oncology，2018; DOI：10.1200 / PO.17.00302)
9/29/2018: CT45 is a biomarker for treatment response and prognosis in ovarian cancer (Coscia F et al. Cell 2018; 175:159-70)
9/23/2018: Promising results of combination therapy with Atezolizuman and nab-paclitaxel in triple-negative breast cancer (ASCO Post: http://www.ascopost.com/News/59027 2018; July 5 2018. Last updated 9/14/2018)
9/22/2018: CAR-T cell may eventually become a way of treating colorectal cancer (Magee MS，et al. Cancer Immunol Res 2018; DOI：10.1158 / 2326-6066.CIR-16-0362)
9/16/2018: Bevacizumab in the Primary Treatment of Ovarian Cancer extended disease-free survival (Burger A et al. N Engl Med 2011; 365:2473-83; FDA: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm610664.htm)
9/15/2018: Safety and activity of combined use of export protein inhibitor with dexamethasone in relapsed/refractory multiple myeloma (Chen C et al. Blood 2018; 131:855-63)
9/9/2018: Microbiome as potential target of treatment for pancreatic cancer (Pushalkar S et al. Cancer Discov 2018; 8:403-16)
9/1/2018: Gene test can spare extended endocrine therapy in low-risk breast cancer (Poage GM et al. ASCO 2018; abstr 516)
9/1/2018: Gene test can spare extended endocrine therapy in low-risk breast cancer (Poage GM et al. ASCO 2018; abstr 516)
8/26/2018: Oral Taxane showed good activity and tolerance in metastatic breast cancer (Seidman AD et al. J Clin Onc 2018; 36: suppl 1042)
8/25/2018: No Pap smear screening among some women in the new USPSTF cervical cancer guideline (https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/cervical-cancer-screening2)
8/19/2018: Tumor Treating Fields in combination with pacliexel raised survival in recurrent ovarian cancer patients (Vergote I et al. Gynecol Oncol. doi: 10.1016/j.ygyno.2018.07.018)
8/18/2018: Blood-based marker for early detection of kidney cancer (Scelo G et al. Clin Cancer Res 2018; doi: 10.1158/1078-0432.CCR-18-1496)
8/12/2018: Efficacy and safety of Talimogene Laherparepvec in combination with ipilimumab in advanced melanoma (Chesney J et al. J Clin Onc 2018; 36: 1658-67)
8/11/2018: Nivolumab plus Ipilimumab improves survival versus Sunitinib in advanced renal cell carcinoma (Motzer RJ et al. N Engl J Med 2018: 378: 1277-90)
8/5/2018: PD-1blockade before lung cancer resection (Forde PM et al. N Engl J Med 2018;378:1976-86)
8/4/2018: A new strategy utilizing the fragile part of tumor cells to treat cancer (Wang H et al. Nature Communication 2018; 9: 2791)
7/29/2018: Olaparib plus Vistusertib showed promise in endometrial cancer and other types of cancers (Westin SN et al. J Clin Oncol 2018; 36 suppl; abstr 5504)
7/28/2018: Death rate of liver cancer is rising quickly in the U.S. (https://www.cdc.gov/cancer/liver/index.htm)
7/22/2018: Sentinel lymph node biopsy can be safely avoided in some breast cancer patients who received pre-operative therapy (Sisó C et et. 2018 European Breast Cancer Conference abstr 104; Van der Norodaa et al. 2018 European Breast Cancer Conference abstr 20)
7/21/2018: Recombinant poliovirus treats glioblastoma (Annick Desjardins, et al. N Engl J Med 2018; 379:150-61)
7/15/2018: Most early breast cancer may forego chemotherapy guided by 21-gene assay (Sparano JA et al. N Engl J Med 2018; 379: 111-21)
7/14/2018: Blood test to screen early stage of lung cancer with high specificity (Oxnard GR et al. J Clin Oncol. 2018; 36: suppl; abstr LBA8501)
7/8/2018: Flight attendants may have higher incidence of multiple cancers (McNeely E et al. Environmental Health 2018; 17:49)
7/7/2018: Adjuvant modified FOLFIRINOX achieved significantly longer survival in resected pancreatic cancer (Conroy T et al: 2018 ASCO Ann Meeting. Abstr LBA4001)
6/30/2018: Promising drug that can “freeze” and stop the spread of cancer cells (Xu L et al. Nature Commuicat 2018; 9:2454)
6/24/2018: Dacomitinib improves survival in NSCLC patients with activating EGFR mutations (MOk TS et al. J Clin Onc 2018; June 4. DOI: 10.1200/JCO.2018.78.7994)
6/23/2018: Polatuzumab vedotin and bendamustine/rituximab combo improved outcome of diffuse large B-cell lymphoma (Sehn LH et al. J Clin Oncol 2018; 36 (suppl; abstr 7507))
6/17/2018: Pre-op chemo and radiation increased overall survival in resectable pancreatic cancer (van Tienhoven G et al. J Clin Oncol 2018;36: suppl; abstr LBA4002)
6/16/2018: Lorlatinib shows anti-tumor activity in ALK-positive NSCLC (Shaw AT et. AACR, 2018; abstr CT044)
6/10/2018: Immuno-chemotherapy may become the new standard for first line treatment for squamous NSCLC (Paz-Ares LG et al. ASCO (Am Asso Clin Onc) 2018; abstr 105; Gandhi L et al. N Eng J Med 2018; 378: 2078-92)
6/9/2018: Post-operative chemo-radiatioin does not improve survival compared with chemotherapy in gastric cancer (Cats A，et al. Lancet Oncol 2018; doi：10.1016 / S1470-2045）
6/3/2018: Immuotherapy-chemotherapy combo extends survival as first line therapy for stage IV NSCLC (non-squamous) (Gandhi et al. AACR (Am Asso Cancer Res) 2018; abstr CT075; Gandhi L et al. N Eng J Med 2018; doi: 10.1056/NEJMoa1801005; Reck M et al. Ann Onc 2017; 28 (11))
6/2/2018: Six months of adjuvant Trastuzumab is non-inferior to 12 months (Earl H. et al. J Clin Oncol 36, 2018; suppl; abstr 506)
5/27/2018: Wound-healing in mice triggers growth of dormant tumors (Krall JA et al. Sci Translational Med 2018; 10: DOI: 10.1126/scitranslmed.aan3464)
5/26/2018: Delay in surgery for non-small cell lung cancer can result in upstaging and prognosis (Serna-Gallegos DR et al. Am Asso Thoracic Surg 2018; Abstr 67)
5/20/2018: FDA Alert: Monotherapy with Pembrolizumab or tezolizumab in clinical trials may reduce survival among uroepithelial cancer patients with low PD-L1 expression (https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm608253.htm)
5/19/2018: Beta blockers may help to improve response to immunotherapy in melanoma (Walkins, JL et al Cancer 2015; 121:3444-51; Kololus KM et al. Oncoimmunology 2018; 7:issue 3 https://doi.org/10.1080/2162402X.2017.1405205)
5/14/2018: Export protein inhibitor is active in refractory myeloma (Chen, C et al. Blood 2018; 131: 855-63)
5/10/2018: New progress in the treatment of unresectable cholangiocarcinoma (Javle M et al: J Clin Oncol 2018; 36:276-82; Goyal L et al. 2017 ESMO Congress 2017: Abstr O-020; Lowery MA 2017 ASCO Annual Meeting. Abstr 4015; Diaz Let al 2017 ESMO Congress. Abstr 386P )
5/6/2018: Long term outcome of neoadjuvant versus post-operative chemotherapy in early breast cancer (Early breast cancer trialists’ collaborative group. The Lancet 2018; 19: 27-39)
5/5/2018: New therapy may cause highly aggressive prostate cancer self-destruction (Nguyen HG et al. Science Transl Med 2018; 10: May 2)
4/29/2018: Can chemotherapy really induce metastases? (Karagiannis GS et al. ci transl Med 2017; 9:pii.eaan0026; Harney AS et al. Cancer Disciv 2015; 5: 932-43; DeMichele A. et al. N Engl J Med 2017: 377: 2287-9)
4/28/2018: Apalutamide delays metastasis in prostate cancer (Smith MR et al. N Engl J Med 2018; 378:1408-18)
4/22/218: Novel combination therapy using BRAF blockage may prolong disease-free survival in metastatic colon cancer (van Cutsem E et al. J Clin Onc 2018; 36: suppl 627)
4/21/2018: Luciferase from deep sea creature is used to determine efficacy of tumor immunotherapy (Mortta H et al. Sci Rep 2018; doi:10.1038/s41598-017-18606-1)
4/16/2018: Surgical management of gastric cancer (Cunningham D et al. N Engl J Med 2006; 355: 11-20; Bonnot PE et al. 2018 Gastrointestinal Cancers Symposium; Oral presentation)
4/1/2018: Low fat diet may enhanced drug activity of abiraterone (Szmulewitz RZ wt al. J Clin Onc 2017; 35 suppl 6S; abstr 176)
3/31/2018: Brentuximab Vedotin and chemotherapy for stage III and IV Hodgkin’s lymphoma (Connors JM et al. N Eng J Med 2018; 378:331-44)
3/25/2018: Triple therapy effective in refractory mantle cell lymphoma (Jerkeman M et al. Lancet Haematol. 2018; 5: e109-16)
3/24/2018: 5α-reductase inhibitor does not increase high-grade prostate cancer (Wallerstedt A, J Natl Cancer Inst 2018; Mar 14. doi: 10.1093/jnci/djy036)
3/18/2018: Atezolizumab and Bevacizumab combo extends PFS in locally advanced or metastatic renal cell carcinoma (Motzer R et al. Genitourinary Can Sym 2018; Feb. Abstr 578)
3/17/2018: Larger surgical margin width reduces local recurrence in early-stage breast cancer (Houssami N, et al. Cancer Biol Med. 2014;doi:10.7497/j.issn. 2095-3941.2014.02.001; Moran MS, et al. Ann Surg Oncol. 2014;doi:10.1245/s10434-014-3481-4; Shah C, et al. San Antonio Breast Can Symp Dec. 5-9, 2017; Abst GS5-01)
3/11/2018: Venetoclax benefits elderly acute myeloid leukemia patients (Wei, A et al. Am Society Hemat oral presentation 2017 Dec; Lin TL et al. JCO 2016; 34 (15): suppl 7007)
3/10/2018: Does supplement calcium increase the risk of precancerous serrated colon polyps? (Crockett SD et al. Gut 2017 published March 1 on line. http://dx.doi.org/10.1136/gutjnl-2017-315242)
3/4/2018: Pazotanib improves PFS in extensive state small cell lung carcinoma but with toxicity (Sun J-M et al. Br J Cancer 2018; Jan. 8. doi:10.1038/bjc.2017.465)
3/3/2018: Rigosertib used in MDS and MDS progressed to acute myeloid leukemia (Navada SC et al. Leuk Res 2018 Jan;64:10-16. doi: 10.1016)
2/25/2018: Target therapy for brain tumors (P Brastianos et al. Nat Genet 2013: 45:: 285-9; Rostami E et al. Acta Neurochir (Wien) 2017; 159: 2217-21;; Muller H. Curr Opinion Endo Metab Res 2018; Feb 21 https://doi.org/10.1016/j.coemr.2018.02.003)
2/24/2018: Nivolumab with or without Ipilimumab improves outcomes in MSI-H metastatic colorectal cancer (T André et al. 2018 Gastrointestinal Cancers Sym 2018; abstr 553; Overman MR et al. 2018 Gastrointestinal Cancers Sym 2018; abstr 554)
2/18/2018: Consumption of ultra-processed foods and cancer risk (Fiolet T et al. BMJ 2018; 360: k322 published Feb. 14. doi: https://doi.org/10.1136/bmj.k322)
2/17/2018: Hyperthermic intraperitoneal chemotherapy in ovarian cancer (van Driel WJ et al. New Engl J Med 2018; 378:230-40)
2/11/2018: Uterine Neoplasms (Klopp A et al. Pract Radia Onco 2014; 4: 137-44; Miller S. et ak. Gynecol 2012; 125:771; Homesley HD et al. J Clic Onn 2007; 25: 526-31; Greven K et al. Int J Rdiat Oncol Biol Phy 2004; 59: 168-73; Hogberg T et al. Eur J Cancer 2010: 46: 2422-31; Second A et al. Gynecol Oncol 2007; 107: 285-91)
2/10/2018: Colonic biofilms may contact carcinogenic bacteria (Dejea CM et al. Science 2018; 359:592)
2/4/2018: Blood test for early detection of solid tumors (Cohen JD et al. Science 2018: Jan. 18)
2/3/2018: Intraoperative molecular imaging helps to find more cancerous lung nodules (Predina JD et al. Ann Surg 21017; 266 (6): e42-4)
1/28/2018: Cancer can override circadian rhythm to survive (Bu Y et al. Nature Cell Biol 2017; 20: 104-15)
1/27/2018: Post-operative chemotherapy beneficial following preoperative chemoradiotherapy and resection in gastroesophageal cancer (Mondadori AA et al, JAMA Onc 2018; 4: 31-8)
1/21/2018: Anti-PD-1/PD-L1 therapy and hyperprogression of advanced lung cancer (Caramella FR et al. 2017 ESMO Congress 2017; Abstr 1306PD; Dercle CS et al. Clin Cancer Res 2016: 23: 1920-8; Kato S et al. Clin Cancer Res 2017; 23: 4242-50)
1/20/2018: Gefitinib is active in a subgroup of advanced esophageal cancer (Patty RD et al. J Clin Onc 2017; 35: 2279-87)
1/14/2018: ASCO practice guideline for systemic treatment of stage IV non-small cell lung cancer ( Hanna N e al. J Clin Onc 2017: 35:3484-515)
1/13/2018: How to combat therapy-driven cancer cell growth (Barker HE et al. Nat Rev Cancer 2015; 15:409-25 ; Hangai S et al. PNAS 2016; 113-3844-9; Huang Q et al. Nat Med 2011; 17: 860-6; Mantovani A et al Nature 2008; 454:436-44; Serhan CN Nature 2014; 510:92-101; Sulciner ML el. J Exp Med 2018; 215:115)
1/7/2018: Hypoxia-inducible factor-2α antagonist has activity against advanced renal cell carcinoma (Courtney KP et al. J Clin Onc 2017 Dec 19:doi: 10.1200/JCO.2017.74.2627)
1/6/2018: Cancer death rate in the U.S. continues to decline (Siegel RL et al. CA: A cancer J for Clinicians. Jan. 4, 2018; )
1/1/2018: Near-infrared triggered release of cancer drugs to deliver more drugs with less side-effects (Goodman AM et al. PNAS 2017; 114: 12149-24)